Making the Call In LR-MDS
Exploring Treatments That Improve Outcomes and Decrease Transfusion Burden
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Arber DA, et al. Blood. 2022;140(11):1200-1228.
Evaluation of lenalidomide vs placebo in non-transfusion dependent low risk del(5q) MDS patients. Final results of Sintra-REV ohase 3 international multicenter clinical trial.
Cadenas FL, et al. Blood. 2022;140(suppl 1): 1109–1111.
Luspatercept in patients with lower-risk MDS.
Fenaux R, et al. N Engl J Med. 2020;382(2):140-151.
Efficacy and safety results from the COMMANDS trial: a phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naïve transfusion-dependent patients with lower-risk MDS.
Garcia-Manero G, et al. ASCO 2023; June 2-5, 2023; Chicago, IL. Abstract 7003.
Multilineage and safety results from the COMMANDS trial in transfusion-dependent, ESA-naïve patients with very low-, low-, or intermediate-risk MDS.
Garcia-Manero G, et al. EHA 2024; June 13-16, 2024; Madrid, Spain. Abstract P780.
Efficacy and safety of luspatercept vs epoetin alfa in ESA-naive patients with transfusion-dependent lower-risk MDS: full analysis of the COMMANDS trial.
Garcia-Manero G, et al. ASH 2023; December 9-12, 2023; San Diego, CA. Abstract 193.
The 5th edition of the World Health Organization classification of hematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms.
Khoury JD, et al. Leukemia. 2022;36(7):1703-1719.
Imetelstat in patients with lower-risk MDS who have relapsed or are refractory for ESAs (IMerge): a multinational, randomized, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, et al. Lancet 2024;403:249-260.
Long-term evaluation of luspatercept in ESA-intolerant/refractory patients with lower-risk MDS in the phase 3 MEDALIST study.
Santini V, et al. ASH 2023; December 9-12, 2023; San Diego, CA. Abstract 915.
Randomized phase III study of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent patients with lower-risk non-del(5q) MDS and ineligible for or refractory to ESAs.
Santini V, et al. J Clin Oncol. 2016;34:2988–2996.
Lenalidomide with or without erythropoietin in transfusion-dependent ESA-refractory lower-risk MDS without 5q deletion.
Toma A, et al. Leukemia. 2016;30:897–905.
Determinants of lenalidomide response with or without ESAs in MDS: the HOVON89 trial.
Van de Loosdrecht AA, et al. Leukemia. 2024;38:840-850.
Guidelines
NCCN Guidelines®: Myelodysplastic Syndrome (MDS), version 2.2024
Greenberg PL, et al. J Natl Compr Canc Netw. 2024.
Clinician Resources
Aplastic Anemia & MDS International Foundation
European Hematology Association (EHA)
Leukemia & Lymphoma Society
MDS Foundation, Inc.
Molecular International Prognostic Scoring System (IPSS-M) Risk Calculator
Management of newly diagnosed, treatment-naive LR-MDS
Module 1
| Faculty: | Andrew Kuykendall, MD; Robert S. Ohgami, MD, PhD, FCAP |
| Release: | 07/31/2024 |
| Expiration: | 07/31/2025 |
Management of erythropoiesis-stimulating agent (ESA)-refractory, LR-MDS with RS
Module 2
| Faculty: | Andrew Kuykendall, MD; Alyssa Mae de Castro, PharmD, BCOP |
| Release: | 08/08/2024 |
| Expiration: | 08/08/2025 |
Management of treatment-naïve LR-MDS
Module 3
| Faculty: | Andrew Kuykendall, MD; Aditi Shastri, MD |
| Release: | 08/15/2024 |
| Expiration: | 08/15/2025 |
Individualized 1L Therapeutic Decision-Making in LR-MDS with Del5Q
Module 4
| Faculty: | Andrew Kuykendall, MD; Aditi Shastri, MD |
| Release: | 08/22/2024 |
| Expiration: | 08/22/2025 |
